Avadhesh Kumar Singh

Avadhesh Kumar Singh has a diverse work experience in the field of scientific research. Avadhesh Kumar began their career as a Postdoctoral Researcher at the University of Gothenburg in 2014. During their time there, they focused on investigating the immunological role of Vdelta1 cells in the pathogenesis of multiple sclerosis (MS). Avadhesh Kumar specifically identified that Vdelta1 T cells produce high levels of IFN-g during MS relapse and found that treatment with natalizumab reduced IFN-g production to normal levels. In 2019, Avadhesh Kumar Singh joined Fluicell AB as an R&D Scientist, contributing to the company's research and development efforts. Avadhesh Kumar later advanced to the role of Lead Scientist. The end dates for their roles at Fluicell AB are not specified.

Avadhesh Kumar Singh's education history begins with a Bachelor of Science (B.Sc.) degree in Chemistry from the University of Allahabad, where they studied from 2001 to 2004. Avadhesh Kumar then pursued a Master of Science (M.Sc.) degree in Biotechnology at Madurai Kamaraj University from 2005 to 2007. Following this, they went on to complete their Doctor of Philosophy (Ph.D.) in Immunology at the All India Institute of Medical Sciences (AIIMS) from 2007 to 2013.